P. Kent Hawryluk - Sep 12, 2024 Form 3 Insider Report for MBX Biosciences, Inc. (MBX)

Role
President & CEO, Director
Signature
/s/ Richard Bartram, attorney-in-fact
Stock symbol
MBX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
3
Date filed
9/12/2024, 07:34 PM
Next filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MBX Common Stock 198K Sep 12, 2024 Direct
holding MBX Common Stock 282K Sep 12, 2024 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MBX Stock Option (right to buy) Sep 12, 2024 Common Stock 313K $3.25 Direct F2
holding MBX Stock Option (right to buy) Sep 12, 2024 Common Stock 718K $7.82 Direct F3
holding MBX Series A Convertible Preferred Stock Sep 12, 2024 Common Stock 168K Direct F4
holding MBX Series A Convertible Preferred Stock Sep 12, 2024 Common Stock 28.8K By Trust F1, F4
holding MBX Series B Convertible Preferred Stock Sep 12, 2024 Common Stock 116K Direct F4
holding MBX Series B Convertible Preferred Stock Sep 12, 2024 Common Stock 6.4K By Trust F1, F4
holding MBX Series C Convertible Preferred Stock Sep 12, 2024 Common Stock 80.8K By Trust F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F2 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date.
F3 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 15, 2023, subject to the Reporting Person's continued service on each such vesting date.
F4 Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney